Tonix Pharmaceuticals Holding Corp. announced the publication of two Phase 1, single-dose, open-label pharmacokinetic studies of TNX-102 SL, now marketed as TONMYA (cyclobenzaprine HCl sublingual tablets), in the journal Clinical Pharmacology in Drug Development. The studies compared multiple sublingual prototype formulations with oral immediate-release cyclobenzaprine and evaluated TNX-102 SL at 2.8 mg and 5.6 mg under fasting and fed conditions, reporting rapid absorption, higher relative bioavailability versus oral dosing, no observed food effect, and characterization of the active metabolite norcyclobenzaprine. The results have already been presented in the published manuscript. The company also noted that TONMYA was commercially launched in the U.S. in November 2025 following FDA approval on August 15, 2025 for fibromyalgia in adults.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603051615PRIMZONEFULLFEED9666815) on March 05, 2026, and is solely responsible for the information contained therein.